ARQUIMEA Drives Dialogue Between Science, Technology and Society to Advance the Fight Against ALS

• The company has collaborated with Molefy Pharma, the CSIC and the Government of the Canary Islands in an event that brought together experts to address the scientific, care-related and social challenges of Amyotrophic Lateral Sclerosis.

 

Canary Islands, 19 June 2026. ARQUIMEA has participated in the organisation of the event “ALS in the Canary Islands: Understanding to Move Forward. Science, Care and Socio-health Commitment“, an initiative promoted by Molefy Pharma together with the Spanish National Research Council (CSIC) and the Government of the Canary Islands, on the occasion of World ALS Day.

The event brought together researchers, healthcare professionals, institutional representatives and experts from the biotechnology sector in Tenerife to analyse the challenges posed by Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease affecting around 4,500 people in Spain and between 120 and 130 patients in the Canary Islands.

The gathering provided a forum to address both the scientific advances in research and the care-related, economic and social impact that the disease has on patients, their families and the healthcare system.

Driving Knowledge Transfer to Generate Impact

ARQUIMEA’s participation in this initiative is part of its commitment to promoting scientific and technological innovation as a tool to address some of society’s greatest challenges.

Through its activities in strategic sectors such as healthcare, biotechnology, artificial intelligence, space and defense, the company is committed to connecting research, technological development and industrial capabilities to accelerate the delivery of innovative solutions to the market.

The event highlighted the importance of collaboration between research institutions, technology companies, public administrations and healthcare professionals in transforming scientific knowledge into advances that have a tangible impact on people’s lives.

Science and Innovation in the Face of Neurodegenerative Diseases

One of the main focal points of the event was the presentation of progress around AP-2, a therapeutic candidate developed from research conducted at the CSIC, whose clinical development is being driven by Molefy Pharma.

The research focuses on the TDP-43 protein, one of the primary biological alterations associated with ALS, and represents one of the most promising lines of work for gaining a deeper understanding of the mechanisms involved in the progression of the disease.

During the event, clinical specialists and researchers agreed that the advances achieved in the study of ALS could also contribute to improving the understanding of other neurodegenerative diseases, broadening the potential impact of this research.

A Shared Commitment to Innovation and Social Well-Being

For ARQUIMEA, supporting initiatives that foster dialogue between science, technology and society is part of its vision of innovation as a driver of progress.

The company maintains a strong commitment to advancing research and development projects in strategic fields with the potential to generate a positive impact on society, promoting collaborative ecosystems that accelerate technology transfer and knowledge generation.

The holding of this event further reinforces the role of the Canary Islands as an increasingly relevant environment for biomedical research and technological innovation, consolidating an ecosystem in which scientific institutions, companies and public administrations work together to address some of the most complex challenges of our time.